How therapeutic drug monitoring can help to personalise dosing of anti-tnf monoclonal antibodies in patients with chronic inflammatory diseases

• In: SYMPOSIUM: ENABLING PERSONALIZED MEDICINE: GETTING THE FRAMEWORK RIGHT? on Tuesday, 15 April 2014, 10:30-12:00
• At: PSWC, Melbourne (Australia) (2014)
• Type: Presentation
• By: VANDE CASTEELE, Niels (KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium)
• Abstract:

  Therapeutic drug monitoring (TDM) of anti-tumour necrosis factor (anti-TNF) monoclonal antibodies with measurements of drug serum levels and anti-drug antibodies (ADA) holds the potential to further unravel how pharmacokinetics (PK) and immunogenicity influence disease activity and clinical (non-)response in rheumatoid arthritis and inflammatory..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login